Status:
COMPLETED
Exemestane As Treatment In Neoadjuvant Setting For Operable Breast Cancer Patients
Lead Sponsor:
Pfizer
Conditions:
Breast Neoplasms
Eligibility:
FEMALE
Phase:
PHASE2
Brief Summary
To evaluate clinical and pathologic response rates following primary hormonal therapy by exemestane (Aromasin®)
Eligibility Criteria
Inclusion
- Post-menopausal patients with unilateral breast cancer T2 to T4, N0-1, M0, non inflammatory, operable, hormonal receptors positive
Exclusion
- Patients with bilateral breast cancer T4d, inflammatory, non operable, hormonal receptors negative
Key Trial Info
Start Date :
November 1 2001
Trial Type :
INTERVENTIONAL
End Date :
September 1 2006
Estimated Enrollment :
46 Patients enrolled
Trial Details
Trial ID
NCT00174343
Start Date
November 1 2001
End Date
September 1 2006
Last Update
April 22 2011
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Bordeaux, France
2
Pfizer Investigational Site
Clermont-Ferrand, France
3
Pfizer Investigational Site
Montpellier, France
4
Pfizer Investigational Site
Poitiers, France